Vigilant Capital Management’s Novo Nordisk NVO Stock Holding History

Vigilant Capital Management’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$61K	Hold	752	–	–	﹤0.01%	257
2023 Q1	$60K	Sell	752 -918	-55%	-$65.1K	﹤0.01%	255
2022 Q4	$113K	Hold	1,670	–	–	0.01%	199
2022 Q3	$83K	Buy	1,670 +914	+121%	+$49K	0.01%	236
2022 Q2	$42K	Sell	756 -1,124	-60%	-$62.4K	﹤0.01%	291
2022 Q1	$104K	Hold	1,880	–	–	0.01%	234
2021 Q4	$105K	Hold	1,880	–	–	0.01%	252
2021 Q3	$90K	Buy	1,880 +756	+67%	+$36.5K	0.01%	215
2021 Q2	$47K	Buy	+1,124	New	+$43.6K	﹤0.01%	275
2019 Q1	–	Sell	-600	Closed	-$14K	–	453
2018 Q4	$14K	Buy	+600	New	+$13.3K	﹤0.01%	351
2018 Q2	–	Sell	-434	Closed	-$11K	–	501
2018 Q1	$11K	Buy	434 +284	+189%	+$7.46K	﹤0.01%	354
2017 Q4	$4K	Hold	150	–	–	﹤0.01%	385
2017 Q3	$4K	Hold	150	–	–	﹤0.01%	284
2017 Q2	$3K	Buy	+150	New	+$3.03K	﹤0.01%	261
2016 Q4	–	Sell	-782	Closed	-$16K	–	291
2016 Q3	$16K	Hold	782	–	–	﹤0.01%	239
2016 Q2	$21K	Buy	+782	New	+$21.4K	﹤0.01%	224

Other funds holding NVO

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vigilant Capital Management's NVO Position: Q2 2023 in Review

Vigilant Capital Management held its Novo Nordisk (NVO) position steady in Q2 2023 at 752 shares worth $61K. The position accounts for ﹤0.01% of the portfolio, ranked #257.

Vigilant Capital Management first reported a position in NVO in Q2 2016 and has held it in 16 quarters since. The position peaked at $113K in Q4 2022. 1,197 funds tracked by Wall St. Rank hold NVO as of Q2 2023.

Vigilant Capital Management held 752 shares of Novo Nordisk worth $61K as of Q2 2023.
Vigilant Capital Management left its Novo Nordisk share count unchanged in Q2 2023.
Novo Nordisk made up ﹤0.01% of Vigilant Capital Management's portfolio in Q2 2023, its #257 holding.
Vigilant Capital Management first reported a position in Novo Nordisk in Q2 2016 and has held it in 16 quarters since.
Vigilant Capital Management's Novo Nordisk position peaked at $113K in Q4 2022.
1,197 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2023.

Based on Vigilant Capital Management's 13F filing for Q2 2023, filed 8 Aug 2023.